VHL mutation analysis in patients with isolated central nervous system haemangioblastoma

Brain. 2007 Mar;130(Pt 3):836-42. doi: 10.1093/brain/awl362. Epub 2007 Jan 29.

Abstract

Haemangioblastomas of the CNS are a cardinal feature of von Hippel-Lindau (VHL) disease, a dominantly inherited multisystem familial cancer syndrome caused by germline mutation of the VHL tumour suppressor gene. We investigated the frequency of VHL mutations in 188 patients presenting with a single haemangioblastoma, no family history of VHL disease and no evidence of retinal or abdominal manifestations of the disease at the time of diagnosis. We found that approximately 4% of patients had a detectable VHL mutation and all of these cases presented age 40 years or less. Although the identification of a germline VHL mutation has important consequences for the patient (e.g. risk of further CNS and extra-CNS tumours) and their relatives, four patients had germline VHL missense mutations [C162Y, D179N and R200W (two patients)] that may represent haemangioblastoma-only and/or low penetrance mutations. Approximately 5% of patients without a detectable VHL mutation subsequently developed a further 'VHL type tumour' (in most cases a further CNS haemangioblastoma). These findings suggest that a subset of patients with apparently sporadic CNS haemangioblastoma will have a germline VHL mutation but may not be at risk for developing classical VHL disease and a further group may be mosaic for a germline VHL mutation that cannot be detected in blood cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Central Nervous System Neoplasms / complications
  • Central Nervous System Neoplasms / genetics*
  • Child
  • Cohort Studies
  • DNA Mutational Analysis / methods
  • DNA, Neoplasm / genetics
  • Family Health
  • Female
  • Germ-Line Mutation / genetics
  • Hemangioblastoma / complications
  • Hemangioblastoma / genetics*
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Mutation, Missense / genetics
  • Risk Factors
  • Von Hippel-Lindau Tumor Suppressor Protein / genetics*
  • von Hippel-Lindau Disease / complications
  • von Hippel-Lindau Disease / diagnosis
  • von Hippel-Lindau Disease / genetics*

Substances

  • DNA, Neoplasm
  • Von Hippel-Lindau Tumor Suppressor Protein